Avania Strengthens Leadership Team with Appointment of Four New Executives
BILTHOVEN, Netherlands and BOSTON, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Avania, the…
Oculis and EURETINA Announce the Winner of the Ramin Tadayoni Award 2025
ZUG, Switzerland, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq:…
NEOGEN SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Neogen Corporation – NEOG
NEW ORLEANS, Sept. 03, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder…
Atypical AI Debuts ExamJam SAT: Personalized Prep That Feels Like a Human Tutor
San Francisco, CA , Sept. 03, 2025 (GLOBE NEWSWIRE) -- Atypical AI…
Ai20x Launches as a Solana-Powered Experiment in Sustainable Crypto Design
Paris, France, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Ai20x, a Solana-powered experiment…
Senseonics Signs Memorandum of Understanding with Ascensia Diabetes Care to Take Over Commercialization and Distribution of Eversense 365
September 03, 2025 17:17 ET | Source: Senseonics Holdings, Inc. CGM commercial…
Sotera Health Announces Secondary Offering of Common Stock
September 03, 2025 16:57 ET | Source: Sotera Health Services, LLC CLEVELAND,…
UPDATE — vTv Therapeutics to Participate in Upcoming September Investor Conferences
September 03, 2025 16:57 ET | Source: vTv Therapeutics Inc. HIGH POINT,…
Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock
September 02, 2025 21:33 ET | Source: Mineralys Therapeutics, Inc. RADNOR, Pa.,…
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI IQLIK(lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimers Disease Under Fast Track Status
LEQEMBI IQLIK, if approved for initiation dosing, would be the first and…
